BLAINJECTIONINJECTABLE
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
TRAZIMERA (trastuzumab-qyyp) by Pfizer is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2019.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAZIMERA (trastuzumab-qyyp) is a Pfizer-sponsored monoclonal antibody biosimilar that targets HER2/neu receptors, approved in 2019 as a therapeutic option for HER2-positive cancers. It works by antagonizing HER2 signaling to inhibit tumor cell proliferation and survival. This is a biosimilar formulation of the reference trastuzumab molecule.
$5MPart D
PeakTRAZIMERA is at peak lifecycle stage with modest Medicare spending, indicating a mature market position within a crowded biosimilar competitive set.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRAZIMERA offers exposure to a mature, high-competition biosimilar market where success depends on pricing discipline, payer relationships, and clinical evidence positioning rather than commercial launch novelty. Career growth is constrained by market saturation and biosimilar parity, making it suitable for professionals seeking specialization in access, managed care, or competitive intelligence.
Brand Manager
Worked on TRAZIMERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.